Abstract
We report the case of an HIV-1-infected patient, treated with anti-CD20 monoclonal antibody for a B-cell lymphoma previously treated by autologous stem cell transplant. He suffered from chronic COVID19 and we monitored by plasma SARS-CoV-2 RNA by highly sensitive droplet-based digital PCR technology (ddPCR). Under tocilizumab therapy and despite a first clinical improvement biologically associated with decreasing inflammatory markers, a slight increase of SARS-CoV-2 RNAaemia quantified by ddPCR was highlighted, confirming the absence of viral efficacy of this treatment and predicting the subsequent observed deterioration. As expected, his complete recovery, finally achieved after COVID-19 convalescent plasmatherapy, strictly paralleled plasma SARS-CoV-2 RNA clearance. With these results, we confirmed the interest of SARS-CoV-2 RNAaemia monitoring by ddPCR in COVID-19 patients, particularly during treatment, and firstly showed that this new and specific biomarker could be helpful to select eligible patient for anti-IL6 receptors therapy considering the variable levels of efficacy recently observed with such therapy.
【초록키워드】 COVID-19, Treatment, SARS-CoV-2, Efficacy, COVID19, therapy, Biomarker, monoclonal antibody, inflammatory markers, digital PCR, Deterioration, B-cell lymphoma, Patient, Clinical improvement, plasma, SARS-CoV-2 RNA, receptor, convalescent, COVID-19 patients, anti-CD20, complete recovery, anti-IL6, slight increase, tocilizumab therapy, clearance, Cell, autologous, subsequent, treated, absence, suffered, expected, quantified, eligible, 【제목키워드】 COVID-19, PCR, Digital, SARS-CoV-2 RNA, B-cell, Against,